Antifungal therapy in oropharyngeal mycotic infections.
Oral and pharyngeal candidiasis is a significant infection, particularly in immunosuppressed persons. Candidiasis may be evident as red or white lesions and may produce symptoms. In immunosuppressed persons, oral candidiasis may lead to extensive regional involvement and to systemic infection and can result in death. Because of the significance and prevalence of candidiasis, the recognition and management of infection are important.
Cancer Control Agency of British Columbia, Vancouver, Canada.
J B
JB
Epstein
D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009059:Mouth Diseases / Q000188:drug therapy*; D009181:Mycoses / Q000188:drug therapy*; D010608:Pharyngeal Diseases / Q000188:drug therapy*
D000891:Anti-Infective Agents, Local; D000935:Antifungal Agents